Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter MoreThe Motley Fool · 1 day ago
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowZacks Investment Research · 2 days ago
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to KnowZacks Investment Research · 3 days ago
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a BetZacks Investment Research · 5 days ago
CRISPR Therapeutics Announces Chief Financial Officer TransitionGlobeNewsWire · 6 days ago
Where Will CRISPR Therapeutics Stock Be in 2030?The Motley Fool · Oct 18, 2026CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$1.19 | -$0.94 | Beat |
| May 4, 2026 | -$1.19 | -$1.28 | Miss |
| Feb 12, 2026 | -$1.15 | -$1.37 | Miss |
| Nov 10, 2025 | -$1.26 | -$1.17 | Beat |
| Aug 5, 2025 | -$1.47 | -$2.40 | Miss |
| May 6, 2025 | -$1.27 | -$1.58 | Miss |